Vivos Therapeutics, Inc. (NASDAQ:VVOS) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) have received a consensus recommendation of “Hold” from the five research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $4.9167.

A number of research firms have weighed in on VVOS. Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, January 21st. Ascendiant Capital Markets cut their target price on shares of Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating for the company in a research note on Wednesday, December 3rd. Zacks Research upgraded shares of Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, December 1st. Finally, HC Wainwright started coverage on Vivos Therapeutics in a report on Monday, November 17th. They issued a “buy” rating and a $7.00 price objective on the stock.

Institutional Trading of Vivos Therapeutics

Several large investors have recently made changes to their positions in the company. XTX Topco Ltd acquired a new position in Vivos Therapeutics in the 2nd quarter valued at $65,000. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Vivos Therapeutics during the second quarter worth $220,000. Connective Capital Management LLC acquired a new stake in shares of Vivos Therapeutics in the third quarter valued at about $620,000. Acorn Wealth Advisors LLC acquired a new stake in shares of Vivos Therapeutics in the fourth quarter valued at about $30,000. Finally, DRW Securities LLC lifted its stake in shares of Vivos Therapeutics by 179.5% in the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after buying an additional 74,441 shares in the last quarter. 26.35% of the stock is currently owned by hedge funds and other institutional investors.

Vivos Therapeutics Trading Up 1.3%

Shares of VVOS stock opened at $1.54 on Wednesday. Vivos Therapeutics has a 1-year low of $1.42 and a 1-year high of $7.95. The company has a market cap of $16.13 million, a price-to-earnings ratio of -0.87 and a beta of 6.93. The company has a debt-to-equity ratio of 3.31, a current ratio of 0.78 and a quick ratio of 0.78. The stock has a 50 day simple moving average of $1.87 and a 200-day simple moving average of $2.68.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.